Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 1998

View Archived Issues

Connetics: Q4 and FY 1997 highlights

Life Medical Sciences updates shareholders

Inhale Therapeutic Systems: Q4 and FY 1997 highlights

New agents for IBS from Nippon Shinyaku

Novel mitomycin C derivative reported by Sagami

Potent and safe new quinolones from Daiichi

New implant for delivery of LHRH agonists

Novel compound MK6059 isolated by Meiji Seika/Mitsubishi Chemical

Wyeth-Ayerst describes synthesis and pharmacological profile of new agent for stroke

PLA2 inhibitors --BM-16.2115, mepacrine and manoalide-- reduce human leukocyte chemotaxis

Institute of Microbial Chemistry discovers new antibacterial/cytotoxic antibiotic

SGLT inhibitors under evaluation at Tanabe as antidiabetic agents

Antibradycardic M2 receptor antagonists prepared at Yamanouchi

Warning issued for Duract related to potential hepatotoxicity

Safety warnings issued by FDA for Hismanal

Idec evaluates humanized anti-gp39 antibody in phase I

GeneMedicine and Corange progress in cancer alliance

Lilly describes second-generation NK1 antagonist

New antiinflammatory agents prepared by Brazilian academics

Vorozole safe and effective in phase II EORTC study

Preclinical profile of S-4661, a new carbapenem, characterized

Macritonin clinical trial update

Topoisomerase I inhibitor tested in phase I trial

Two combinations compared for treatment of multidrug-resistant falciparum malaria

Targeted Genetics to report tgDCC-E1A clinical data

Anti-Candida activity of voriconazole compared to other antifungal agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...